MADRIGAL PHARMACEUTICALS, INC.
MDGLAPI behind this page
MDGL Q1 2026 request
Playground key active
/api/financials?ticker=MDGL&year=2026&quarter=1
Pick an endpoint and run the request.Income Statement
| Metric | Q1 2026 | Q1 2025 | YoY |
|---|---|---|---|
| Revenue (Q) | — | — | — |
Show Business Segments breakouts |
|||
| Reportable Segment | 311,337 | 137,250 | +126.8% |
Show — breakouts |
|||
| Revenue | 311,337 | 137,250 | +126.8% |
| Operating Costs And Expenses (Q) | — | — | — |
Show — breakouts |
|||
| Operating Costs And Expenses | 26,847 | 4,513 | +494.9% |
| Research And Development Expense Excluding Acquired In Process Cost (Q) | — | — | — |
Show — breakouts |
|||
| Research And Development Expense Excluding Acquired In Process Cost | 108,692 | 44,172 | +146.1% |
Show Counterparty Name breakouts |
|||
| Suzhou Ribo Life Science Co. Ltd. And Ribocure Pharmaceuticals AB | 48.3 | — | — |
| Selling, General & Administrative (Q) | — | — | — |
Show — breakouts |
|||
| Selling, General & Administrative | 268,521 | 167,876 | +60.0% |
| Operating Expenses (Q) | — | — | — |
Show — breakouts |
|||
| Operating Expenses | 404,060 | 216,561 | +86.6% |
| Operating Income (Q) | — | — | — |
Show — breakouts |
|||
| Operating Income | -92,723 | -79,311 | -16.9% |
| Interest Income (Q) | — | — | — |
Show — breakouts |
|||
| Interest Income | 8,243 | 9,370 | -12.0% |
| Interest Expense (Q) | — | — | — |
Show — breakouts |
|||
| Interest Expense | -7,819 | -3,297 | -137.2% |
| Other Non-Operating Income (Expense) (Q) | — | — | — |
Show — breakouts |
|||
| Other Non-Operating Income (Expense) | -2,092 | — | — |
| Net Income (Q) | — | — | — |
Show Business Segments breakouts |
|||
| Reportable Segment | -94,391 | -73,238 | -28.9% |
Show Equity Components breakouts |
|||
| Retained Earnings | -94,391 | -73,238 | -28.9% |
Show — breakouts |
|||
| Net Income | -94,391 | -73,238 | -28.9% |
| EPS (Basic) (Q) | — | — | — |
Show — breakouts |
|||
| EPS (Basic) | -3.25 | -2.61 | -24.5% |
| EPS (Diluted) (Q) | — | — | — |
Show — breakouts |
|||
| EPS (Diluted) | -3.25 | -2.61 | -24.5% |
| Wtd Avg Shares (Basic) (Q) | — | — | — |
Show — breakouts |
|||
| Wtd Avg Shares (Basic) | 29,032,422 | 28,085,234 | +3.4% |
| Wtd Avg Shares (Diluted) (Q) | — | — | — |
Show — breakouts |
|||
| Wtd Avg Shares (Diluted) | 29,032,422 | 28,085,234 | +3.4% |
| Cost of Revenue (Q) | — | — | — |
Show Business Segments breakouts |
|||
| Reportable Segment | -26,847 | -4,513 | -494.9% |
| Comprehensive Income (Q) | — | — | — |
Show — breakouts |
|||
| Comprehensive Income | -94,182 | -73,317 | -28.5% |
| Other Comprehensive Income (Q) | — | — | — |
Show Equity Components breakouts |
|||
| Accumulated Other Comprehensive Income | 209 | -79 | +364.6% |
Show — breakouts |
|||
| Other Comprehensive Income | 209 | -79 | +364.6% |
| Labor And Related Expense (Q) | — | — | — |
Show Business Segments breakouts |
|||
| Reportable Segment · Research And Development Expense | -15,097 | -9,035 | -67.1% |
| Reportable Segment · Selling General And Administrative Expenses | -83,605 | -48,361 | -72.9% |
| Professional Fees (Q) | — | — | — |
Show Business Segments breakouts |
|||
| Reportable Segment · Research And Development Expense | -84,547 | -28,797 | -193.6% |
| Reportable Segment · Selling General And Administrative Expenses | -131,252 | -88,014 | -49.1% |
Balance Sheet
| Metric | Q1 2026 | Q1 2025 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents (Q) | — | — | — |
Show — breakouts |
|||
| Cash & Cash Equivalents | 227,033 | 183,646 | +23.6% |
| Restricted Cash Current (Q) | — | — | — |
Show — breakouts |
|||
| Restricted Cash Current | 5,155 | — | — |
| Available For Sale Securities Debt Securities Current (Q) | — | — | — |
Show — breakouts |
|||
| Available For Sale Securities Debt Securities Current | 585,738 | 659,422 | -11.2% |
| Accounts Receivable (Q) | — | — | — |
Show — breakouts |
|||
| Accounts Receivable | 187,356 | 61,428 | +205.0% |
| Inventory (Q) | — | — | — |
Show — breakouts |
|||
| Inventory | 112,070 | 55,241 | +102.9% |
| Prepaid Expenses & Other Current Assets (Q) | — | — | — |
Show — breakouts |
|||
| Prepaid Expenses & Other Current Assets | 64,955 | — | — |
Show Counterparty Name breakouts |
|||
| Suzhou Ribo Life Science Co. Ltd. And Ribocure Pharmaceuticals AB | 11.7 | — | — |
| Total Current Assets (Q) | — | — | — |
Show — breakouts |
|||
| Total Current Assets | 1,182,307 | 987,979 | +19.7% |
| Non-Current Assets | |||
| Property, Plant & Equipment (Q) | — | — | — |
Show — breakouts |
|||
| Property, Plant & Equipment | 8,035 | 1,901 | +322.7% |
| Intangible Assets (Q) | — | — | — |
Show — breakouts |
|||
| Intangible Assets | 7,284 | 4,639 | +57.0% |
| Operating Lease Right-of-Use Assets (Q) | — | — | — |
Show Geography breakouts |
|||
| West Conshohocken, Pennsylvania | 4 | — | — |
Show — breakouts |
|||
| Operating Lease Right-of-Use Assets | 6,203 | — | — |
| Other Non-Current Assets (Q) | — | — | — |
Show — breakouts |
|||
| Other Non-Current Assets | 23,498 | — | — |
| Total Assets (Q) | — | — | — |
Show — breakouts |
|||
| Total Assets | 1,227,327 | 996,629 | +23.1% |
| Current Liabilities | |||
| Accounts Payable (Q) | — | — | — |
Show — breakouts |
|||
| Accounts Payable | 60,801 | 42,056 | +44.6% |
| Accrued Liabilities (Q) | — | — | — |
Show — breakouts |
|||
| Accrued Liabilities | 275,761 | 124,165 | +122.1% |
| Operating Lease Liability Current (Q) | — | — | — |
Show — breakouts |
|||
| Operating Lease Liability Current | 1,697 | 1,016 | +67.0% |
| Total Current Liabilities (Q) | — | — | — |
Show — breakouts |
|||
| Total Current Liabilities | 338,259 | 167,237 | +102.3% |
| Non-Current Liabilities | |||
| Long-Term Debt (Q) | — | — | — |
Show — breakouts |
|||
| Long-Term Debt | 340,330 | 118,005 | +188.4% |
| Operating Lease Liabilities (Q) | — | — | — |
Show — breakouts |
|||
| Operating Lease Liabilities | 5,284 | 750 | +604.5% |
| Liabilities Noncurrent (Q) | — | — | — |
Show — breakouts |
|||
| Liabilities Noncurrent | 345,614 | 118,755 | +191.0% |
| Total Liabilities (Q) | — | — | — |
Show — breakouts |
|||
| Total Liabilities | 683,873 | 285,992 | +139.1% |
| Long-Term Debt (Q) | — | — | — |
Show Debt Instrument breakouts |
|||
| The Financing Agreement · Secured Debt | 350 | — | — |
Show — breakouts |
|||
| Long-Term Debt | 340,330 | — | — |
| Stockholders' Equity | |||
| Common Stock (Q) | — | — | — |
Show — breakouts |
|||
| Common Stock | 2 | 2 | 0.0% |
| Additional Paid In Capital Common Stock (Q) | — | — | — |
Show — breakouts |
|||
| Additional Paid In Capital Common Stock | 2,727,227 | 2,585,666 | +5.5% |
| Accumulated Other Comprehensive Income (Q) | — | — | — |
Show — breakouts |
|||
| Accumulated Other Comprehensive Income | 1,082 | 389 | +178.1% |
| Retained Earnings (Q) | — | — | — |
Show — breakouts |
|||
| Retained Earnings | -2,184,857 | -1,875,420 | -16.5% |
| Total Stockholders' Equity (Q) | — | — | — |
Show Equity Components breakouts |
|||
| Accumulated Other Comprehensive Income | 1,082 | 389 | +178.1% |
| Additional Paid In Capital | 2,727,227 | 2,585,666 | +5.5% |
| Common Stock | 2 | 2 | 0.0% |
| Retained Earnings | -2,184,857 | -1,875,420 | -16.5% |
Show — breakouts |
|||
| Total Stockholders' Equity | 543,454 | 710,637 | -23.5% |
| Total Liabilities & Equity (Q) | — | — | — |
Show — breakouts |
|||
| Total Liabilities & Equity | 1,227,327 | 996,629 | +23.1% |
| Preferred Stock Shares Issued (Q) | — | — | — |
Show — breakouts |
|||
| Preferred Stock Shares Issued | 2,369,797 | — | — |
| Preferred Stock Shares Outstanding (Q) | — | — | — |
Show Equity Components breakouts |
|||
| Preferred Stock | 2,369,797 | 2,369,797 | 0.0% |
Show — breakouts |
|||
| Preferred Stock Shares Outstanding | 2,369,797 | — | — |
Cash Flow Statement
| Metric | YTD Q1 2026 | YTD Q1 2025 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Stock-Based Compensation (Q) | — | — | — |
Show — breakouts |
|||
| Stock-Based Compensation | 34,018 | 20,931 | +62.5% |
| Depreciation & Amortization (Q) | — | — | — |
Show — breakouts |
|||
| Depreciation & Amortization | 386 | 379 | +1.8% |
| Amortization Of Financing Costs And Discounts (Q) | — | — | — |
Show — breakouts |
|||
| Amortization Of Financing Costs And Discounts | 449 | 436 | +3.0% |
| Operating Lease Right Of Use Asset Periodic Reduction Increase (Q) | — | — | — |
Show — breakouts |
|||
| Operating Lease Right Of Use Asset Periodic Reduction Increase | 408 | 56 | +628.6% |
| Other Non-Cash Items (Q) | — | — | — |
Show — breakouts |
|||
| Other Non-Cash Items | -2,440 | — | — |
| Change in Accounts Receivable (Q) | — | — | — |
Show — breakouts |
|||
| Change in Accounts Receivable | -52,880 | -7,606 | -595.2% |
| Change in Prepaid & Other Assets (Q) | — | — | — |
Show — breakouts |
|||
| Change in Prepaid & Other Assets | -40,649 | -9,456 | -329.9% |
| Change in Inventory (Q) | — | — | — |
Show — breakouts |
|||
| Change in Inventory | -22,187 | -21,173 | -4.8% |
| Increase Decrease In Accounts Payable Trade (Q) | — | — | — |
Show — breakouts |
|||
| Increase Decrease In Accounts Payable Trade | 3,584 | -1,543 | +332.3% |
| Increase Decrease In Accrued Liabilities (Q) | — | — | — |
Show — breakouts |
|||
| Increase Decrease In Accrued Liabilities | 4,287 | -530 | +908.9% |
| Increase Decrease In Accrued Interest Net Of Interest Received (Q) | — | — | — |
Show — breakouts |
|||
| Increase Decrease In Accrued Interest Net Of Interest Received | 1,980 | 2,853 | -30.6% |
| Net Cash from Operations (Q) | — | — | — |
Show — breakouts |
|||
| Net Cash from Operations | -167,435 | -88,891 | -88.4% |
| Investing Activities | |||
| Purchases of Investments (Q) | — | — | — |
Show — breakouts |
|||
| Purchases of Investments | -157,829 | -130,812 | -20.7% |
| Proceeds From Sale And Maturity Of Available For Sale Securities (Q) | — | — | — |
Show — breakouts |
|||
| Proceeds From Sale And Maturity Of Available For Sale Securities | 353,869 | 294,690 | +20.1% |
| Capital Expenditures (Q) | — | — | — |
Show — breakouts |
|||
| Capital Expenditures | -3,849 | — | — |
| Net Cash from Investing (Q) | — | — | — |
Show — breakouts |
|||
| Net Cash from Investing | 192,191 | 163,878 | +17.3% |
| Financing Activities | |||
| Proceeds From Stock Options Exercised (Q) | — | — | — |
Show — breakouts |
|||
| Proceeds From Stock Options Exercised | 2,329 | 8,640 | -73.0% |
Show Award Type breakouts |
|||
| Employee Stock Option | 2.3 | 8.6 | -73.3% |
| Net Cash from Financing (Q) | — | — | — |
Show — breakouts |
|||
| Net Cash from Financing | 2,329 | 8,640 | -73.0% |
| Supplemental | |||
| Right Of Use Asset Obtained In Exchange For Operating Lease Liability (Q) | — | — | — |
Show — breakouts |
|||
| Right Of Use Asset Obtained In Exchange For Operating Lease Liability | 1,672 | — | — |
| Unpaid Capital Expenditures (Q) | — | — | — |
Show — breakouts |
|||
| Unpaid Capital Expenditures | 2,979 | — | — |
| Other Cash Flow | |||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations (Q) | — | — | — |
Show — breakouts |
|||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | 1,320 | — | — |
| Net Change in Cash (Q) | — | — | — |
Show — breakouts |
|||
| Net Change in Cash | 28,405 | 83,627 | -66.0% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents (Q) | — | — | — |
Show — breakouts |
|||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 232,188 | 188,646 | +23.1% |
Values in thousands USD. Source: SEC EDGAR 10-Q filing.